Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. - Wikidata - awgldk - TriplyDB

Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role.

Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role.

http://www.wikidata.org/entity/Q36318136

about

Reciprocal relationship of T regulatory cells and monocytic myeloid-derived suppressor cells in LP-BM5 murine retrovirus-induced immunodeficiency Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma.Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment Downregulation of CD40 expression contributes to the accumulation of myeloid-derived suppressor cells in gastric tumors.Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity.Multifunctional CD40L: pro- and anti-neoplastic activity.Soluble co-signaling molecules predict long-term graft outcome in kidney-transplanted patients Soluble CD40 ligand contributes to dendritic cell-mediated T-cell dysfunction in HIV-1 infection.T cells compete by cleaving cell surface CD27 and blocking access to CD70-bearing APCs.Platelets promote allergic asthma through the expression of CD154 CD40 controls CXCR5-induced recruitment of myeloid-derived suppressor cells to gastric cancer The role of soluble CD40L in immunosuppression Effect of Danhong Injection Combined with Naoxintong Tablets on Prognosis and Inflammatory Factor Expression in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention.A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinosta Decreased Levels of Circulating Cancer-Associated Protein Biomarkers Following Bariatric Surgery.Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody.Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial Angiotensin-converting enzyme and the tumor microenvironment: mechanisms beyond angiogenesis.Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy.Decreased Mean Platelet Volume is Associated with Cervical Cancer Development Co-stimulate or Co-inhibit Regulatory T Cells, Which Side to Go?Regulation of platelet membrane protein shedding in health and disease.Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death.A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas.CD40 ligand-expressing recombinant vaccinia virus promotes the generation of CD8(+) central memory T cells.Gene-Set Reduction for Analysis of Major and Minor Gleason Scores Based on Differential Gene-Set Expressions and Biological Pathways in Prostate Cancer.Mean platelet volume, platelet distribution width and carcinoembryonic antigen to discriminate gastric cancer from gastric ulcer.Soluble CD40-ligand (sCD40L, sCD154) plays an immunosuppressive role via regulatory T cell expansion in HIV infection.Principal component analysis identifies patterns of cytokine expression in non-small cell lung cancer patients undergoing definitive radiation therapy.Binding of Platelets to Lymphocytes: A Potential Anti-Inflammatory Therapy in Rheumatoid Arthritis.Platelet indices in laryngeal cancer.Proteomic biomarkers in body fluids associated with pancreatic cancer.

P2860

Q33573202-B10E1FE9-8AAC-43D4-B024-C7D35D953184 Q33614030-05A02D77-B243-449C-9D0A-BF3EE3833021 Q33718737-42E56DA7-49D4-4E3E-9EEE-763B3646E321 Q33844271-B105B659-F436-4985-91E3-B1A829B48E53 Q33855420-536A5383-740E-4A4A-A711-C2A9826478C2 Q34422566-06A85AAF-DAC8-4A22-A190-BF6DE76733E4 Q34639457-2917D817-0922-40DB-964C-486AD3FF117D Q35772650-A555FD2E-522B-46FF-9C89-D80986944D6A Q36359499-88FC752A-B580-4AF6-909A-41C96BF0091E Q36473192-3A2ED78D-26EC-4870-AAFC-EC92B90D4FE6 Q36629448-ED1D4856-54F4-4B46-9CD8-326841BA1071 Q36643641-251B9DCF-DD22-4A05-83AA-8A40709DD304 Q36721631-6624C8F7-6F74-4137-9ECF-5D20DF0E843B Q37010668-535D3535-B063-4B74-86E5-C7CBECBA8697 Q37142991-D8C69E0C-9F1C-40A2-80E4-C7CC2B564F54 Q37477372-08EEA4BE-C0A8-476B-8714-D44E118AD4E7 Q37639541-92ED9C16-B959-4D9B-998F-BF9DF5A17BB2 Q37658381-29E1056E-EA80-4046-BF99-44EE81F4B403 Q37684364-9CA1D1D9-6D84-4CBC-BB22-D5DF8B15EDD4 Q38112273-D4F2F0AA-FB3D-45CD-A97E-9818FA2F016F Q38120535-25B09472-5F66-4F6D-B9B1-3BBB37A681C9 Q38658084-2CE5ACAB-03C6-48D0-B085-C2AB0FFAFDA5 Q38897638-4EEA419F-3ED3-406B-9897-FC3AD5E21363 Q38919547-E3FE31A4-7AC9-46B6-8C6A-91E9FA75BD7A Q39003293-A9843135-FC04-41AE-B80C-E71186137D8F Q40533062-2CC9DE29-EC75-4CC5-B64E-FABEE41ED344 Q40912746-E79AE41E-CA91-448C-8AFE-707B1ACE59F0 Q41078668-4576DA30-63F7-4ABC-9E47-BF8C4D6C3BFF Q42044302-E259421B-A4A1-47B7-BF4A-89F4BDFE3F9C Q42212835-83DB5E10-FA38-4166-B5A9-D506D82222B3 Q42362026-239874A2-0791-4571-8C94-9BC7940AC6EC Q48176964-7E3A5DB3-0F4F-4E5A-8792-50F7C4C6E490 Q49494131-90E370A1-1BBF-40A2-B592-D941690C377F Q52584324-08FD0E2C-BDE3-4440-B40A-FF6CF7491217

P2860

Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role.

http://www.wikidata.org/entity/Q36318136

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role.

@ast

Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role.

@en

type

label

Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role.

@ast

Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role.

@en

prefLabel

Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role.

@ast

Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role.

@en

P1433

Q36318136-8A6FF58F-DA1C-4A1D-A20B-1B52C643B1A2

P1476

Q36318136-1908BC5F-87FB-4B91-BD14-6FFD796A09F8

P2093

Q36318136-07C2F519-EBA9-46D6-90A8-01D4DD6341B0

Q36318136-087D4923-DDBD-48A1-BA72-D4D5F205D666

Q36318136-216D3DC0-65D3-4412-976D-293B48BB8519

Q36318136-46C52475-2AF5-4FFA-9FA0-E4C16C79D554

Q36318136-76A34D3C-D059-40A1-AB2A-E41AF069048E

Q36318136-CE296C98-9DF7-4865-834D-AAB7AD147D34

Q36318136-DA212A92-ABAF-4230-973C-4C10244C3D4F

Q36318136-EADA139A-C2B6-4EF7-89D2-663841AD212E

Q36318136-F2773B45-D724-4E88-82FA-42B750185F0A

P2860

Q36318136-0D690726-43F2-413C-9F21-81635F260FE6

Q36318136-0D945265-A3E7-4216-B0A1-6AC3A1B5B71F

Q36318136-1000A3EB-8715-4740-B800-9C3EF94058C2

Q36318136-101B1A18-72FA-4267-A10C-42E08F1F6154

Q36318136-105046E7-99A3-425C-98B1-3A88FC26883A

Q36318136-13B35F7F-A4C0-4F22-B4B4-547AF65F61BB

Q36318136-1AAA7D80-684F-4751-BF91-E05EA8BCF784

Q36318136-25CC57D4-5DE0-467A-AB78-24F847FF0C4C

Q36318136-25FA85EF-E6D3-45C0-A457-B28B0BC205F7

Q36318136-2877A71C-1F01-4F55-8D0F-EFBD6FBEEB82

P304

Q36318136-852E3FE3-07FA-49AF-9BA2-C5898CEA7BCE

P31

Q36318136-3787F188-6D4E-4A64-B6FF-D2BC8CC05551

P356

Q36318136-0D8DAF18-E2EE-44CB-9295-19D36D8EF4E1

P407

Q36318136-BE1D02E6-CCB3-4F27-86AB-F77C36CA935E

P433

Q36318136-EB639A7C-F36A-46E8-9616-BE8C243A7F1A

P478

Q36318136-9592E277-04BA-4AF8-A746-58ABF9DCF7CC

P577

Q36318136-906BD79F-C6C0-4E55-B3F2-42DD44DE715C

P5875

Q36318136-1476C833-2E8B-4D2F-AD0B-B0C44A70C885

P698

Q36318136-8422B983-DF01-4FD8-8CCF-312C1199ED52

P932

Q36318136-A74117BC-789A-4E01-A131-79094919F414

P356

BLOOD-2012-05-427799

P1433

P1476

Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role.

@en

P2093

Alessandra Jales

http://www.w3.org/2001/XMLSchema#string

Austin Anderson

http://www.w3.org/2001/XMLSchema#string

Caroline Jochems

http://www.w3.org/2001/XMLSchema#string

James L Gulley

http://www.w3.org/2001/XMLSchema#string

Jeffrey Schlom

http://www.w3.org/2001/XMLSchema#string

Jianping Huang

http://www.w3.org/2001/XMLSchema#string

Kwong Y Tsang

http://www.w3.org/2001/XMLSchema#string

Ravi A Madan

http://www.w3.org/2001/XMLSchema#string

Tara Talaie

http://www.w3.org/2001/XMLSchema#string

P2860

CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Myeloid-derived suppressor cells as regulators of the immune system

Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus

Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease

Platelet activation in patients with colorectal cancer

Soluble receptors in human disease

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Signalling pathways of the TNF superfamily: a double-edged sword

Abiraterone and increased survival in metastatic prostate cancer

P304

3030-3038

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2012-05-427799

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

120

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230762627

http://www.w3.org/2001/XMLSchema#string

P698

22932804

http://www.w3.org/2001/XMLSchema#string

P932

3471513

http://www.w3.org/2001/XMLSchema#string